A Craig Lockhart - JoVE Visualize

Showing results (41-50 of 92) with videos related to

Pageof 10

Sort By:

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006

The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 studyKenneth R Hande, Anne Hagey, Jordan Berlin, et al.

Cancer Chemotherapy and Pharmacology|October 14, 2014

Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxelJohn Sarantopoulos, Alain C Mita, James L Wade, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2013

Physician and stakeholder perceptions of conflict of interest policies in oncologyA Craig Lockhart, Marcia S Brose, Edward S Kim, et al.

Molecular Pharmaceutics|August 2, 2019

Folate Receptor α-Targeted <sup>89</sup>Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast CancerGyu Seong Heo, Lisa Detering, Hannah P Luehmann, et al.

The Lancet. Oncology|March 3, 2015

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 studyBohuslav Melichar, Antoine Adenis, A Craig Lockhart, et al.

Investigational New Drugs|August 31, 2017

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignanciesXiaofei Zhou, Shubham Pant, John Nemunaitis, et al.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 1, 2005

A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreasKaren L Tedesco, Jordan Berlin, Mace Rothenberg, et al.

Cancer Research|December 17, 2008

Overexpression of OATP1B3 confers apoptotic resistance in colon cancerWooin Lee, Abbes Belkhiri, A Craig Lockhart, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2016

A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast CancerCynthia X Ma, Cesar Sanchez, Feng Gao, et al.

Molecular Imaging and Biology|November 15, 2015

Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid TumorsA Craig Lockhart, Yongjian Liu, Farrokh Dehdashti, et al.

Pageof 10

Showing results (41-50 of 92) with videos related to

Sort By:

Pageof 10

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006

The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 studyKenneth R Hande, Anne Hagey, Jordan Berlin, et al.

Cancer Chemotherapy and Pharmacology|October 14, 2014

Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxelJohn Sarantopoulos, Alain C Mita, James L Wade, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2013

Physician and stakeholder perceptions of conflict of interest policies in oncologyA Craig Lockhart, Marcia S Brose, Edward S Kim, et al.

Molecular Pharmaceutics|August 2, 2019

Folate Receptor α-Targeted <sup>89</sup>Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast CancerGyu Seong Heo, Lisa Detering, Hannah P Luehmann, et al.

The Lancet. Oncology|March 3, 2015

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 studyBohuslav Melichar, Antoine Adenis, A Craig Lockhart, et al.

Investigational New Drugs|August 31, 2017

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignanciesXiaofei Zhou, Shubham Pant, John Nemunaitis, et al.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 1, 2005

A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreasKaren L Tedesco, Jordan Berlin, Mace Rothenberg, et al.

Cancer Research|December 17, 2008

Overexpression of OATP1B3 confers apoptotic resistance in colon cancerWooin Lee, Abbes Belkhiri, A Craig Lockhart, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2016

A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast CancerCynthia X Ma, Cesar Sanchez, Feng Gao, et al.

Molecular Imaging and Biology|November 15, 2015

Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid TumorsA Craig Lockhart, Yongjian Liu, Farrokh Dehdashti, et al.

Pageof 10